Literature DB >> 23622210

Dravet syndrome (severe myoclonic epilepsy in infancy).

Charlotte Dravet1, Hirokazu Oguni.   

Abstract

Severe myoclonic epilepsy in infancy (SMEI) is a rare disease, characterized by febrile and afebrile, generalized and unilateral, clonic or tonic-clonic seizures that occur in the first year of life in an otherwise apparently normal infant. They are later associated with myoclonus, atypical absences, and partial seizures. Developmental delay becomes apparent within the second year of life and is followed by definite cognitive impairment and personality disorders of variable intensity. In the borderline form, children do not present with myoclonic symptoms but have the same general picture. SMEI is a channelopathy and the genetic studies have shown a mutation in the SCN1A gene in 70 to 80% of the patients, including the borderline forms. At present, there are no well-established correlations between genotype and phenotype. The electroencephalograms, often normal at the onset, display both generalized and focal anomalies, without a specific electroencephalographic pattern. As a rule, neuroimaging is normal. All seizure types are resistant to antiepileptic drugs and status epilepticus is frequent. Some drugs have been shown to aggravate the seizures and must be avoided. Two recent drugs have been proved to partially control the convulsive seizures and the status epilepticus. Therefore, it is crucial to diagnose this epilepsy soon after its onset in order to prescribe the most appropriate treatment.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23622210     DOI: 10.1016/B978-0-444-52891-9.00065-8

Source DB:  PubMed          Journal:  Handb Clin Neurol        ISSN: 0072-9752


  44 in total

Review 1.  Inflammatory pathways of seizure disorders.

Authors:  Nicola Marchi; Tiziana Granata; Damir Janigro
Journal:  Trends Neurosci       Date:  2013-12-16       Impact factor: 13.837

2.  Interactions between cannabidiol and Δ9 -tetrahydrocannabinol in modulating seizure susceptibility and survival in a mouse model of Dravet syndrome.

Authors:  Lyndsey L Anderson; Ivan K Low; Iain S McGregor; Jonathon C Arnold
Journal:  Br J Pharmacol       Date:  2020-07-27       Impact factor: 8.739

Review 3.  The genetics of the epilepsies.

Authors:  Christelle M El Achkar; Heather E Olson; Annapurna Poduri; Phillip L Pearl
Journal:  Curr Neurol Neurosci Rep       Date:  2015-07       Impact factor: 5.081

4.  Dynamic changes of depolarizing GABA in a computational model of epileptogenic brain: Insight for Dravet syndrome.

Authors:  P Kurbatova; F Wendling; A Kaminska; A Rosati; R Nabbout; R Guerrini; O Dulac; G Pons; C Cornu; P Nony; C Chiron; P Benquet
Journal:  Exp Neurol       Date:  2016-05-28       Impact factor: 5.330

5.  STXBP1 encephalopathies: Clinical spectrum, disease mechanisms, and therapeutic strategies.

Authors:  Debra Abramov; Noah Guy Lewis Guiberson; Jacqueline Burré
Journal:  J Neurochem       Date:  2020-08-04       Impact factor: 5.372

6.  Cardiac arrhythmia in a mouse model of sodium channel SCN8A epileptic encephalopathy.

Authors:  Chad R Frasier; Jacy L Wagnon; Yangyang Oliver Bao; Luke G McVeigh; Luis F Lopez-Santiago; Miriam H Meisler; Lori L Isom
Journal:  Proc Natl Acad Sci U S A       Date:  2016-10-26       Impact factor: 11.205

Review 7.  Pathogenesis and new candidate treatments for infantile spasms and early life epileptic encephalopathies: A view from preclinical studies.

Authors:  Aristea S Galanopoulou; Solomon L Moshé
Journal:  Neurobiol Dis       Date:  2015-05-09       Impact factor: 5.996

Review 8.  Pharmacotherapy for Dravet Syndrome.

Authors:  Adam Wallace; Elaine Wirrell; Daniel L Kenney-Jung
Journal:  Paediatr Drugs       Date:  2016-06       Impact factor: 3.022

Review 9.  Palliative epilepsy surgery in Dravet syndrome-case series and review of the literature.

Authors:  Brian J Dlouhy; Brandon Miller; Anna Jeong; Mary E Bertrand; David D Limbrick; Matthew D Smyth
Journal:  Childs Nerv Syst       Date:  2016-07-27       Impact factor: 1.475

10.  Economic Evaluation of Stiripentol for Dravet Syndrome: A Cost-Utility Analysis.

Authors:  Jesse Elliott; Bláthnaid McCoy; Tammy Clifford; George A Wells; Doug Coyle
Journal:  Pharmacoeconomics       Date:  2018-10       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.